rQNestin
Phase 1Small molecule
rQNestin is one of 33 small molecule programs targeting Malignant Glioma. It is currently in Phase 1.
1
Indications
1
Total Trials
1
Active Trials
32
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
34 competitors in Malignant Glioma
#DrugCompanyPhaseTrials
1Temodar
CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Approved
Afinitor
NovartisApproved
Norvir
AbbVieApproved
Lynparza
AstraZenecaApproved
Levulan
Sun Pharmaceutical Industries, Inc.Approved
Plaquenil
Jazz PharmaceuticalsApproved
Tafinlar
NovartisApproved
Ziagen
GSKApproved
Revlimid
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Approved
Tylenol
KKenvue Brands
Approved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Malignant Glioma1 trial
A Study of the Treatment of Recurrent Malignant Glioma With rQNestin34.5v.2
Active, not recruiting·—·Phase 1·NCT03152318·62 enrolled
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for rQNestin. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 1[1]
- Company
- DDana-Farber Cancer Institute